Back to Authors

Shereck, Evan

https://orcid.org/0000-0002-3092-7996

Mayo Clinic

Oregon Health & Science University

Citations 6

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone, Lena E. , Logan, Brent R. , Liu, Xuerong , Williams, Olatundun , Dunn, Elizabeth A. , Thakar, Monica S. , Kidd, Sharon A. , Dorsey, Morna J. , O'Reilly, R, Kapoor, Neena , Kapadia, Malika , Jyonouchi, Soma , Chandra, Sharat , Chellapandian, Deepak , Chaudhury, Sonali , Chen, Karin , Rayes, Ahmad , Quigg, Troy C. , Teira, Pierre , Gillio, Alfred P. , Eissa, Hesham, Knutsen, Alan P., Aquino, Victor M. , Shereck, Evan , Lugt, Mark T. Vander , Rozmus, Jacob, Yu, Lolie C. , Shah, Ami J. , Joshi, Avni Y. , Buckley, Rebecca H. , Oved, Joseph H. , Azim, Hisham Abdel, Martinez, Caridad , Sullivan, Kathleen E. , Bleesing, Jack J., Madden, Lisa, Shenoy, Shalini , Seroogy, Christine M. , Rubin, Tamar N. , Licata, Jennifer, Andolina, Jeffrey R. , Burroughs, Lauri M. , Leiding, Jennifer W. , Marsh, Rebecca , Pai, Sung‐Yun , Torgerson, Troy R. , Heimall, Jennifer , Griffith, Linda M. , Puck, Jennifer M. , Dvorak, Christopher C. , Cowan, Morton J. , Liu, Xuerong , Mousallem, Talal , Dorsey, Morna J , O'Reilly, Richard J , Kapoor, Neena , Forbes Satter, Lisa R , Kapadia, Malika , Chandra, Sharat , Ebens, Christen L , Chellapandian, Deepakbabu , Chaudhury, Sonali , Chen, Karin , Dávila Saldaña, Blachy J , Rayes, Ahmad , Quigg, Troy C , Chandrakasan, Shanmuganathan , Bednarski, Jeffrey J , DeSantes, Kenneth B , Teira, Pierre , Gillio, Alfred P , Eissa, Hesham , Aquino, Victor M , Shereck, Evan B , Moore, Theodore Bruce , Caywood, Emi H , Vander Lugt, Mark T , Rozmus, Jacob , Broglie, Larisa A , Yu, Lolie C. , Shah, Ami J , Joshi, Avni Y , Buckley, Rebecca H , Dara, Jasmeen , Oved, Joseph H , Abdel Azim, Hisham , Martinez, Caridad , Prockop, Susan E , Sullivan, Kathleen E , Bleesing, Jack J , Keller, Michael D , Madden, Lisa M , Parikh, Suhag , Shenoy, Shalini , Seroogy, Christine M , Rubin, Tamar , Licata, Jennifer , Andolina, Jeffrey R , Kohn, Donald B , Burroughs, Lauri M , Leiding, Jennifer W , Marsh, Rebecca A , Notarangelo, Luigi D , Pai, Sung-Yun , Torgerson, Troy R , Pulsipher, Michael A. , Heimall, Jennifer , Cuvelier, Geoffrey D E , Griffith, Linda M , Puck, Jennifer M , Dvorak, Christopher C , Cowan, Morton J , Haddad, Elie , Winestone, Lena E , Satter, Lisa Forbes , Ebens, Christen L. , Saldaña, Blachy J. Dávila , Chandrakasan, Shanmuganathan , Knutsen, Alan P. , Broglie, Larisa , Dara, Jasmeen , Abdel‐Azim, Hisham , Prockop, Susan E. , Bleesing, Jack , Keller, Michael D. , Parikh, Suhag , Kohn, Donald B. , Cuvelier, Geoff D.E. , Haddad, Élie

Journal of Human Immunity | July 7, 2026 | Volume: 2 | Issue: 5 | Pages: No page available

10.70962/jhi.20250231 Get It

Black race and Hispanic ethnicity are associated with higher mortality in severe combined immunodeficiency (SCID) following hematopoietic cell transplantation (HCT), though mechanisms remain unclear. We evaluated 796 children with SCID who received nonsibling HCT between 1982 and 2020 using data from the Primary Immune Deficiency Treatment Consortium. Overall survival for Black (aHR 2.47, 95%CI 1.64, 3.71) and Asian/Pacific Islander patients (aHR 1.82, 95%CI 1.00, 3.30) was significantly lower compared with non-Hispanic White patients, while Hispanic patients had lower event-free survival (aHR 1.83, 95%CI 1.27, 2.63) compared with non-Hispanic White patients. Even after adjusting for age and infection, Black patients with SCID had more than twofold hazard of death compared with non-Hispanic White patients. NBS was associated with earlier diagnosis, reduced infection at HCT, and elimination of survival disparities between Black and non-Hispanic White patients. These findings suggest that universal, system-level interventions such as NBS can mitigate disparities in outcomes for children with SCID.
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Alexander, Jessie L. , Saldaña, Blachy J. Dávila , Brazauskas, Ruta , Dammalapati, Sravya Gethika, Griffith, Linda M. , Shah, Ami J. , Shimano, Kristin A. , Ochs, Hans D., Bleesing, Jack , Ebens, Christen L. , Kapadia, Malika, Bauchat, Andrea , Oved, Joseph H. , Eissa, Hesham, Lust, Hannah , Haines, Hilary , Rayes, Ahmad , Madden, Lisa, Shereck, Evan , Miller, Holly, Martinez, Caridad , Rozmus, Jacob, Yu, Lolie C. , Chellapandian, Deepak , Aquino, Victor M., Knutsen, Alan P. , Chong, Hey , Chopek, Ashley, Gillio, Alfred P. , Joshi, Avni Y. , Rangarajan, Hemalatha G. , Andolina, Jeffrey R. , Lugt, Mark T. Vander , Prockop, Susan E. , Shyr, David C. , Sullivan, Kathleen E. , Weinacht, Katja G. , Torgerson, Troy R. , Marsh, Rebecca , Dvorak, Christopher C. , Heimall, Jennifer , Leiding, Jennifer W. , Puck, Jennifer M. , Rawlings, David J. , Cowan, Morton J. , Petrović, Aleksandra , Pai, Sung‐Yun , Burroughs, Lauri M. , Dávila Saldaña, Blachy J , Oved, Joseph H , Lust, Hannah , Rayes, Ahmad , Forbes Satter, Lisa R , Bednarski, Jeffrey J , Chellapandian, Deepakbabu , Joshi, Avni, Rangarajan, Hemalatha G , Andolina, Jeffrey R , Prockop, Susan E , Parikh, Suhag , Torgerson, Troy R , Chan, Alice Y , Haddad, Elie , Pulsipher, Michael A. , Leiding, Jennifer W , Kohn, Donald B , Puck, Jennifer M , Notarangelo, Luigi D , Pai, Sung-Yun , Burroughs, Lauri M , Ebens, Christen L , Dvorak, Christopher C , Shimano, Kristin A , Shah, Ami J , Ochs, Hans D., Kapoor, Neena R. , Keller, Michael D. , Chandrakasan, Shanmuganathan , Talano, Julie‐An , Satter, Lisa Forbes , Moore, Theodore Bruce , DeSantes, Kenneth B , Parikh, Suhag , Haddad, Élie , Kohn, Donald B.

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 5 | Pages: 1783-1798

10.1182/bloodadvances.2025017662 Get It

Abstract Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non–busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Burroughs, Lauri M. , Petrović, Aleksandra , Brazauskas, Ruta , Liu, Xuerong , Griffith, Linda M. , Ochs, Hans D. , Bleesing, Jack , Edwards, Stephanie , Dvorak, Christopher C. , Chaudhury, Sonali , Prockop, Susan E. , Quinones, Ralph, Goldman, Frederick D. , Quigg, Troy C. , Chandrakasan, Shanmuganathan , Smith, Angela R. , Saldaña, Blachy J. Dávila , Thakar, Monica S. , Shenoy, Shalini , Forbes, Lisa R., Martinez, Caridad , Chellapandian, Deepak , Shereck, Evan , Miller, Holly, Kapoor, Neena , Barnum, Jessie L., Chong, Hey , Shyr, David C. , Chen, Karin , Shah, Ami J. , Weinacht, Katja G. , Joshi, Avni Y. , Gillio, Alfred P. , Cuvelier, Geoff D.E. , Keller, Michael D. , Rozmus, Jacob, Torgerson, Troy R. , Haddad, Élie , Sullivan, Kathleen E. , Logan, Brent R. , Puck, Jennifer M. , Pai, Sung‐Yun , Rawlings, David J. , Cowan, Morton J. , Satter, Lisa Forbes , Joshi, Avni, Cuvelier, Geoffrey D E , Forbes Satter, Lisa R , Prockop, Susan E , Dávila Saldaña, Blachy J , Dvorak, Christopher C , Haddad, Elie , Parikh, Suhag , Phelan, Rachel , Abu‐Arja, Rolla , Moore, Theodore Bruce , DeSantes, Kenneth B , Pulsipher, Michael A. , Kohn, Donald B. , Notarangelo, Luigi D , Chandrakasan, Shanmuganathan , Rozmus, Jacob , Shah, Ami J , Keller, Michael D

Blood | April 8, 2020 | Volume: 135 | Issue: 23 | Pages: 2094-2105

10.1182/blood.2019002939 Get It

Abstract Wiskott-Aldrich syndrome (WAS) is an X-linked disease caused by mutations in the WAS gene, leading to thrombocytopenia, eczema, recurrent infections, autoimmune disease, and malignancy. Hematopoietic cell transplantation (HCT) is the primary curative approach, with the goal of correcting the underlying immunodeficiency and thrombocytopenia. HCT outcomes have improved over time, particularly for patients with HLA-matched sibling and unrelated donors. We report the outcomes of 129 patients with WAS who underwent HCT at 29 Primary Immune Deficiency Treatment Consortium centers from 2005 through 2015. Median age at HCT was 1.2 years. Most patients (65%) received myeloablative busulfan-based conditioning. With a median follow-up of 4.5 years, the 5-year overall survival (OS) was 91%. Superior 5-year OS was observed in patients <5 vs ≥5 years of age at the time of HCT (94% vs 66%; overall P = .0008). OS was excellent regardless of donor type, even in cord blood recipients (90%). Conditioning intensity did not affect OS, but was associated with donor T-cell and myeloid engraftment after HCT. Specifically, patients who received fludarabine/melphalan-based reduced-intensity regimens were more likely to have donor myeloid chimerism <50% early after HCT. In addition, higher platelet counts were observed among recipients who achieved full (>95%) vs low-level (5%-49%) donor myeloid engraftment. In summary, HCT outcomes for WAS have improved since 2005, compared with prior reports. HCT at a younger age continues to be associated with superior outcomes supporting the recommendation for early HCT. High-level donor myeloid engraftment is important for platelet reconstitution after either myeloablative or busulfan-containing reduced intensity conditioning. (This trial was registered at www.clinicaltrials.gov as #NCT02064933.)
Measuring pediatric hematology–oncology fellows’ skills in humanism and professionalism: A novel assessment instrument
Kesselheim, Jennifer C. , Bhatia, Nita, Cronin, Angel M., Jubran, Rima , Kent, Paul , Kersun, Leslie S. , Rao, Amulya Nageswara, Rose, Melissa J. , Savelli, Stephanie, Sharma, Mukta , Shereck, Evan , Twist, Clare J. , Wang, Michael , Agrawal, Anurag K. , Rao, Amulya A. Nageswara

Pediatric Blood & Cancer | November 3, 2016 | Volume: 64 | Issue: 5 | Pages: No page available

10.1002/pbc.26316 Get It

AbstractBackgroundEducators in pediatric hematology–oncology lack rigorously developed instruments to assess fellows’ skills in humanism and professionalism.ProcedureWe developed a novel 15‐item self‐assessment instrument to address this gap in fellowship training. Fellows (N = 122) were asked to assess their skills in five domains: balancing competing demands of fellowship, caring for the dying patient, confronting depression and burnout, responding to challenging relationships with patients, and practicing humanistic medicine. An expert focus group predefined threshold scores on the instrument that could be used as a cutoff to identify fellows who need support. Reliability and feasibility were assessed and concurrent validity was measured using three established instruments: Maslach Burnout Inventory (MBI), Flourishing Scale (FS), and Jefferson Scale of Physician Empathy (JSPE).ResultsFor 90 participating fellows (74%), the self‐assessment proved feasible to administer and had high internal consistency reliability (Cronbach's α = 0.81). It was moderately correlated with the FS and MBI (Pearson's r = 0.41 and 0.4, respectively) and weakly correlated with the JSPE (Pearson's r = 0.15). Twenty‐eight fellows (31%) were identified as needing support. The self‐assessment had a sensitivity of 50% (95% confidence interval [CI]: 31–69) and a specificity of 77% (95% CI: 65–87) for identifying fellows who scored poorly on at least one of the three established scales.ConclusionsWe developed a novel assessment instrument for use in pediatric fellowship training. The new scale proved feasible and demonstrated internal consistency reliability. Its moderate correlation with other established instruments shows that the novel assessment instrument provides unique, nonredundant information as compared to existing scales.
Humanism and professionalism education for pediatric hematology‐oncology fellows: A model for pediatric subspecialty training
Kesselheim, Jennifer C. , Atlas, Mark, Adams, Denise M. , Aygün, Banu , Barfield, Ray, Eisenman, Kristen, Fulbright, Joy M. , Garvey, Katharine C. , Kersun, Leslie S. , Rao, Amulya Nageswara, Reilly, Anne, Sharma, Mukta , Shereck, Evan , Wang, Michael , Watt, Tanya , Leavey, Patrick J. , Nageswara Rao, Amulya, Rao, Amulya A. Nageswara , Leavey, Patrick

Pediatric Blood & Cancer | October 12, 2014 | Volume: 62 | Issue: 2 | Pages: 335-340

10.1002/pbc.25253 Get It

BackgroundHumanism and professionalism are virtues intrinsic to the practice of medicine, for which we lack a standard, evidence‐based approach for teaching and evaluation. Pediatric hematology‐oncology (PHO) fellowship training brings new and significant stressors, making it an attractive setting for innovation in humanism and professionalism training.ProcedureWe electronically surveyed a national sample of PHO fellows to identify fellows' educational needs in humanism and professionalism. Next, we developed a case‐based, faculty‐facilitated discussion curriculum to teach this content within pilot fellowship programs. We assessed whether fellowships would decide to offer the curriculum, feasibility of administering the curriculum, and satisfaction of fellow and faculty participants.ResultsSurveys were completed by 187 fellows (35%). A minority (29%) reported that their training program offers a formal curriculum in humanism and/or professionalism. A majority desires more formal teaching on balancing clinical practice and research (85%), coping with death/dying (85%), bereavement (78%), balancing work and personal life (75%), navigating challenging relationships with patients (74%), and depression/burn out (71%). These six topics were condensed into four case‐based modules, which proved feasible to deliver at all pilot sites. Ten fellowship programs agreed to administer the novel curriculum. The majority (90%) of responding fellows and faculty reported the sessions touched on issues important for training, stimulated reflective communication, and were valuable.ConclusionsPediatric hematology‐oncology fellows identify numerous gaps in their training related to humanism and professionalism. This curriculum offers an opportunity to systematically address these educational needs and can serve as a model for wider implementation. Pediatr Blood Cancer 2015;62:335–340. © 2014 Wiley Periodicals, Inc.
Humanism and Professionalism for Pediatric Hematology-Oncology Fellows (HP-PHO)
Kesselheim, Jennifer C. , Atlas, Mark, Adams, Denise M. , Barfield, Raymond , Eisenman, Kristen, Fulbright, Joy M. , Kersun, Leslie S. , Rao, Amulya Nageswara, Sharma, Mukta , Shereck, Evan , Wang, Michael , Watt, Tanya , Aygün, Banu , Rao, Amulya A. Nageswara , Leavey, Patrick J.

MedEdPORTAL | September 29, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.9607 Get It